Kogrel (Clopidogrel)

Clopidogrel is converted in the liver to an active metabolite that irreversibly blocks the P2Y12 ADP receptor on platelets. This inhibition prevents platelet activation and aggregation, key steps in clot formation, thereby reducing the likelihood of arterial thrombosis.

The appropriate dose of Kogrel is determined by a qualified prescriber based on the patient’s clinical condition, renal and hepatic function, and concomitant therapies. Patients should follow the dosing instructions provided by their healthcare professional and the product label.

The safety of clopidogrel in pregnancy and lactation has not been definitively established. It should only be used if the potential benefit justifies the potential risk to the fetus or infant, and the decision must be made by the prescribing clinician.

To request Kogrel, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Kogrel (clopidogrel) belongs to the thienopyridine class and provides irreversible P2Y12 inhibition, similar to prasugrel and ticagrelor. Compared with aspirin, it offers a different mechanism and may be preferred when aspirin alone is insufficient, though individual risk‑benefit profiles guide selection.

Kogrel tablets should be stored at temperatures below 25 °C, in their original packaging, and protected from moisture and direct sunlight. Do not store in a bathroom or near heat sources to maintain product stability.

Kogrel is taken orally, usually with a glass of water. It can be taken with or without food, but patients should follow the specific instructions given by their prescriber to ensure consistent absorption.

The most serious risks include severe or life‑threatening bleeding, such as intracranial hemorrhage or gastrointestinal bleeding, and rare hematologic disorders like thrombotic thrombocytopenic purpura. Patients should seek immediate medical attention if they notice unusual bruising, blood in stool or urine, or severe headache.

Kogrel is contraindicated in patients with active pathological bleeding, known hypersensitivity to clopidogrel or any component of the formulation, and those who have severe hepatic impairment. It should also be used with caution in individuals with a history of stroke or intracranial hemorrhage.